JP2019512210A - Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 - Google Patents

Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 Download PDF

Info

Publication number
JP2019512210A
JP2019512210A JP2018540833A JP2018540833A JP2019512210A JP 2019512210 A JP2019512210 A JP 2019512210A JP 2018540833 A JP2018540833 A JP 2018540833A JP 2018540833 A JP2018540833 A JP 2018540833A JP 2019512210 A JP2019512210 A JP 2019512210A
Authority
JP
Japan
Prior art keywords
seq
cdr
domain
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512210A5 (enExample
Inventor
ニンヤン チャン
ニンヤン チャン
チーチャン アン
チーチャン アン
アニル ケイ． スード
アニル ケイ． スード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2019512210A publication Critical patent/JP2019512210A/ja
Publication of JP2019512210A5 publication Critical patent/JP2019512210A5/ja
Priority to JP2021139610A priority Critical patent/JP7358426B2/ja
Priority to JP2023106822A priority patent/JP2023130411A/ja
Priority to JP2024140677A priority patent/JP2024164139A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
JP2018540833A 2016-02-05 2017-02-06 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法 Pending JP2019512210A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021139610A JP7358426B2 (ja) 2016-02-05 2021-08-30 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2023106822A JP2023130411A (ja) 2016-02-05 2023-06-29 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2024140677A JP2024164139A (ja) 2016-02-05 2024-08-22 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291987P 2016-02-05 2016-02-05
US62/291,987 2016-02-05
PCT/US2017/016659 WO2017136807A1 (en) 2016-02-05 2017-02-06 Egfl6 specific monoclonal antibodies and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021139610A Division JP7358426B2 (ja) 2016-02-05 2021-08-30 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2019512210A true JP2019512210A (ja) 2019-05-16
JP2019512210A5 JP2019512210A5 (enExample) 2020-03-12

Family

ID=59501106

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018540833A Pending JP2019512210A (ja) 2016-02-05 2017-02-06 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2021139610A Active JP7358426B2 (ja) 2016-02-05 2021-08-30 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2023106822A Pending JP2023130411A (ja) 2016-02-05 2023-06-29 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2024140677A Ceased JP2024164139A (ja) 2016-02-05 2024-08-22 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021139610A Active JP7358426B2 (ja) 2016-02-05 2021-08-30 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2023106822A Pending JP2023130411A (ja) 2016-02-05 2023-06-29 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2024140677A Ceased JP2024164139A (ja) 2016-02-05 2024-08-22 Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法

Country Status (12)

Country Link
US (3) US10875912B2 (enExample)
EP (1) EP3411070A4 (enExample)
JP (4) JP2019512210A (enExample)
KR (1) KR20180105704A (enExample)
CN (2) CN113912717B (enExample)
AU (2) AU2017214685B2 (enExample)
BR (1) BR112018015826A2 (enExample)
CA (2) CA3012696C (enExample)
MX (1) MX2018009499A (enExample)
SG (1) SG11201806622PA (enExample)
WO (1) WO2017136807A1 (enExample)
ZA (1) ZA201805051B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017214685B2 (en) * 2016-02-05 2024-03-07 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use
KR102737830B1 (ko) * 2017-10-01 2024-12-03 타이페이 메디컬 유니이버시티 항-egf 유사 도메인 다중 6(egfl6) 항체 및 암 진단 및 치료에서 이의 적용
WO2020141145A1 (en) * 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
CN110951733A (zh) * 2019-11-27 2020-04-03 山西医科大学 一种靶向抑制食管癌EGFL6基因表达的siRNA及构建的表达载体和应用
CN116381251B (zh) * 2023-03-13 2024-06-25 柏定生物工程(北京)有限公司 一种肿瘤标志物诊断试剂盒及其诊断方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150720A1 (en) * 2013-03-15 2014-09-25 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1845108A3 (en) 1994-07-29 2007-10-24 Innogenetics N.V. Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US20030036508A1 (en) 1997-11-22 2003-02-20 John Ford EGF motif protein, EGFL6 materials and methods
CA2425833A1 (en) 2000-10-13 2002-04-18 Hyseq, Inc. Egf motif protein, egfl6 materials and methods
CN101360823A (zh) * 2005-11-24 2009-02-04 财团法人阪大微生物病研究会 重组多价疫苗
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
KR20180005753A (ko) * 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2011137334A1 (en) * 2010-04-30 2011-11-03 The Research Foundation Of State University Of New York Compositions and methods for stimulating immune response against moraxella catarrhalis
AU2012310328A1 (en) 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
AU2017214685B2 (en) * 2016-02-05 2024-03-07 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150720A1 (en) * 2013-03-15 2014-09-25 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

Also Published As

Publication number Publication date
CN113912717B (zh) 2024-05-03
AU2017214685B2 (en) 2024-03-07
US20210130450A1 (en) 2021-05-06
JP2023130411A (ja) 2023-09-20
SG11201806622PA (en) 2018-09-27
CN109562163A (zh) 2019-04-02
US20250145702A1 (en) 2025-05-08
RU2018131611A (ru) 2020-03-05
CA3012696A1 (en) 2017-08-10
US20190031751A1 (en) 2019-01-31
CN113912717A (zh) 2022-01-11
JP7358426B2 (ja) 2023-10-10
WO2017136807A1 (en) 2017-08-10
EP3411070A4 (en) 2019-11-27
NZ744609A (en) 2025-03-28
JP2024164139A (ja) 2024-11-26
US12152071B2 (en) 2024-11-26
RU2018131611A3 (enExample) 2020-05-19
KR20180105704A (ko) 2018-09-28
JP2022008309A (ja) 2022-01-13
CA3298267A1 (en) 2026-03-02
EP3411070A1 (en) 2018-12-12
NZ784700A (en) 2025-05-02
CA3012696C (en) 2026-07-21
CN109562163B (zh) 2022-04-08
BR112018015826A2 (pt) 2019-01-02
US10875912B2 (en) 2020-12-29
AU2017214685A1 (en) 2018-08-09
ZA201805051B (en) 2023-05-31
MX2018009499A (es) 2019-05-06
AU2024203614A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
US11174320B2 (en) HER3 specific monoclonal antibodies for diagnostic and therapeutic use
JP7358426B2 (ja) Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
US12371507B2 (en) CDCP1 antibodies and antibody drug conjugates
JP2017534251A (ja) Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
BR112021009366A2 (pt) proteína de fusão e uso da mesma
CN104470950B (zh) 抗cxadr抗体
US11512141B2 (en) Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
US10729781B2 (en) LGR4 specific monoclonal antibodies and methods of their use
CA2888345C (en) Jam-c antibodies and methods for treatment of cancer
RU2779902C2 (ru) Egfl6-специфические моноклональные антитела и способы их применения
WO2025090760A1 (en) Antibodies specific to scube3 and methods of use
HK40023906A (en) Fgl2 monoclonal antibodies and their use in treating malignant tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211101